WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA (a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259)), has released its 2024 financial report. The company achieved RMB 4.52 billion (USD 558 million) in revenue for the full year, marking a 90.8% year-on-year (YOY) increase. Net profits soared by 277.2% YOY to RMB 1.07 billion (USD 147 million).
Growth Drivers
The significant growth was primarily driven by the continued active development of the global antibody drug conjugate (ADC) and broader bioconjugates market. WuXi XDC has been expanding its market share through its established position as a leading bioconjugate CRDMO service provider. Additionally, the advancement of its projects into later stages has contributed to the financial success.
Customer and Project Expansion
During 2024, WuXi XDC continued to expand its customer base, reaching a cumulative total of 499 clients, with 154 new additions. As of the end of 2024, the total number of integrated projects (iCMC projects) reached 194, including 53 newly signed integrated projects. The company secured 8 PPQ projects and one commercial stage project, with the total backlog growing to USD 991 million, representing a 71.3% YoY increase.
Diversified Project Portfolio
WuXi XDC boasts a diversified project portfolio covering both innovative ADC and broader bioconjugate (XDC) projects. By the end of 2024, the company had 177 integrated ADC projects and 17 integrated XDC projects. In 2024 alone, the group explored over 4,200 molecules of various modalities, including bispecific ADC, dual-payload ADC, DAC, AOC, APC, and ACC.
Manufacturing Capacity Expansion
WuXi XDC has been actively enhancing its manufacturing capabilities. The company launched the BCM2 L2 production line at its Wuxi site and is advancing the construction of its commercial base in Singapore, which is expected to become operational by the end of 2025.-Fineline Info & Tech
Leave a Reply